Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy

Neurobiology of Aging

Volumn 33, Issue 10, 2012, Pages 2491-2505

  Chiba, Shunmei ^a,b   Takada, Erika ^b   Tadokoro, Mamoru ^c   Taniguchi, Taizo ^d   Kadoyama, Keiichi ^d   Takenokuchi, Mariko ^d   Kato, Seiya ^a   Suzuki, Noboru ^b  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b ST MARIANNA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

Degeneration; Dopaminoreceptive cell; Parkinsonism; Tauopathy

Indexed keywords

CASPASE 3; DOPAMINE; LEVODOPA; MUTANT PROTEIN; TAU PROTEIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN REGION; CATECHOLAMINE SYNTHESIS; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUTATIONAL ANALYSIS; NERVE CELL NECROSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; WESTERN BLOTTING;

ANIMALS; ANTIPARKINSON AGENTS; APOPTOSIS; CASPASE 3; CORPUS STRIATUM; DOPAMINERGIC NEURONS; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; MICE; MICE, TRANSGENIC; MUTATION; NEUROFIBRILS; NEUROPSYCHOLOGICAL TESTS; PARKINSONIAN DISORDERS; PUTAMEN; TAU PROTEINS; TAUOPATHIES;

EID: 84864381531     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.11.002     Document Type: Article

References (49)

1. Abeliovich A., Schmitz Y., Fariñas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec 1946, 94:239-247.
3. Arvanitakis Z., Witte R.J., Dickson D.W., Tsuboi Y., Uitti R.J., Slowinski J., Hutton M.L., Lin S.C., Boeve B.F., Cheshire W.P., Pooley R.A., Liss J.M., Caviness J.N., Strongosky A.J., Wszolek Z.K. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat. Disord 2007, 13:230-239.
4. Borchelt D.R., Davis J., Fischer M., Lee M.K., Slunt H.H., Ratovitsky T., Regard J., Copeland N.G., Jenkins N.A., Sisodia S.S., Price D.L. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal 1996, 13:159-163.
5. Castellani R.J., Nunomura A., Lee H.G., Perry G., Smith M.A. Phosphorylated tau: toxic, protective, or none of the above. J. Alzheimers Dis 2008, 14:377-383.
6. Chiba S., Lee Y.M., Zhou W., Freed C.R. Noggin enhances dopamine neuron production from human embryonic stem cells and improves behavioral outcome after transplantation into Parkinsonian rats. Stem Cells 2008, 26:2810-2820.
7. Clark L.N., Poorkaj P., Wszolek Z., Geschwind D.H., Nasreddine Z.S., Miller B., Li D., Payami H., Awert F., Markopoulou K., Andreadis A., D'Souza I., Lee V.M., Reed L., Trojanowski J.Q., Zhukareva V., Bird T., Schellenberg G., Wilhelmsen K.C. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13103-13107.
8. Colebrooke R.E., Humby T., Lynch P.J., McGowan D.P., Xia J., Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur. J. Neurosci 2006, 24:2622-2630.
9. Congdon E.E., Duff K.E. Is tau aggregation toxic or protective?. J. Alzheimers Dis 2008, 14:453-457.
10. Cyr M., Beaulieu J.M., Laakso A., Sotnikova T.D., Yao W.D., Bohn L.M., Gainetdinov R.R., Caron M.G. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11035-11040.
11. Dawson H.N., Cantillana V., Chen L., Vitek M.P. The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J. Neurosci 2007, 27:9155-9168.
12. Fasulo L., Ugolini G., Cattaneo A. Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. J. Alzheimers Dis 2005, 7:3-13.
13. Feinstein S.C., Wilson L. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim. Biophys. Acta 2005, 1739:268-279.
14. Fernagut P.O., Diguet E., Labattu B., Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J. Neurosci. Methods 2002, 113:123-130.
15. Fienberg A.A., Hiroi N., Mermelstein P.G., Song W., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D.B., Cole D.G., Corbett R., Haile C.N., Cooper D.C., Onn S.P., Grace A.A., Ouimet C.C., White F.J., Hyman S.E., Surmeier D.J., Girault J., Nestler E.J., Greengard P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998, 281:838-842.
16. Foster N.L., Gilman S., Berent S., Morin E.M., Brown M.B., Koeppe R.A. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann. Neurol 1988, 24:399-406.
17. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J. Med 2001, 344:710-719.
18. Funderburk S.F., Marcellino B.K., Yue Z. Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. Mt Sinai J. Med 2010, 77:59-68.
19. Götz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci 2008, 9:532-544.
20. Graybiel A.M., Ohta K., Roffler-Tarlov S. Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradients and compartments. J. Neurosci 1990, 10:720-733.
21. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1956-1961.
22. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
23. Ittner L.M., Fath T., Ke Y.D., Bi M., van Eersel J., Li K.M., Gunning P., Götz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15997-16002.
24. Kishore A., Wszolek Z.K., Snow B.J., de la Fuente-Fernandez R., Arwert F., Wijker M., Schulzer M., Calne D.B., Vingerhoets F.J. Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family. Neurology 1996, 47:1588-1590.
25. Kuhn D.M., Francescutti-Verbeem D.M., Thomas D.M. Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity. Ann. N. Y. Acad. Sci 2008, 1139:118-126.
26. Larsen K.E., Fon E.A., Hastings T.G., Edwards R.H., Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci 2002, 22:8951-8960.
27. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet 2000, 25:402-405.
28. Li L., Zhang X., Le W. Autophagy dysfunction in Alzheimer's disease. Neurodegener. Dis 2010, 7:265-271.
29. Lovell M.A., Geiger H., Van Zant G.E., Lynn B.C., Markesbery W.R. Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiol. Aging 2006, 27:909-917.
30. Ma M., Basso D.M., Walters P., Stokes B.T., Jakeman L.B. Behavioral and histological outcomes following graded spinal cord contusion injury in the C57Bl/6 mouse. Exp. Neurol 2001, 169:239-254.
31. Matsuura K., Kabuto H., Makino H., Ogawa N. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods 1997, 73:45-48.
32. Pal P.K., Wszolek Z.K., Kishore A., de la Fuente-Fernandez R., Sossi V., Uitti R.J., Dobko T., Stoessl A.J. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). Parkinsonism Relat. Disord 2001, 7:81-88.
33. Ramalho R.M., Viana R.J., Castro R.E., Steer C.J., Low W.C., Rodrigues C.M. Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol. Med 2008, 14:309-317.
34. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., Guimaraes A., Yue M., Lewis J., Carlson G., Carlson G., Hutton M., Ashe K.H. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci 2005, 25:10637-10647.
35. Reed L.A., Schmidt M.L., Wszolek Z.K., Balin B.J., Soontornniyomkij V., Lee V.M., Trojanowski J.Q., Schelper R.L. The neuropathology of a chromosome 17-linked autosomal dominant parkinsonism and dementia ("pallido-ponto-nigral degeneration"). J. Neuropathol. Exp. Neurol 1998, 57:588-601.
36. Samii A., Markopoulou K., Wszolek Z.K., Sossi V., Dobko T., Mak E., Calne D.B., Stoessl A.J. PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 1999, 53:2097-2102.
37. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
38. Spillantini M.G., Van Swieten J.C., Goedert M. Tau gene mutations in frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17). Neurogenetics 2000, 2:193-205.
39. Takashima A. Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy. J. Alzheimers Dis 2008, 14:371-375.
40. Takenokuchi M., Kadoyama K., Chiba S., Sumida M., Matsuyama S., Saigo K., Taniguchi T. SJLB mice develop tauopathy-induced parkinsonism. Neurosci Lett 2010, 473:182-185.
41. Taniguchi T., Doe N., Matsuyama S., Kitamura Y., Mori H., Saito N., Tanaka C. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett 2005, 579:5704-5712.
42. Taupin P. Adult neurogenesis in mammals. Curr. Opin. Mol. Ther 2006, 8:345-351.
43. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-1316.
44. van den Munckhof P., Gilbert F., Chamberland M., Lévesque D., Drouin J. Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease. J. Neurochem 2006, 96:160-170.
45. Wang Y., Krüger U., Mandelkow E., Mandelkow E.M. Generation of tau aggregates and clearance by autophagy in an inducible cell model of tauopathy. Neurodegener. Dis 2010, 7:103-107.
46. Xie X., Ramkumar V., Toth L.A. Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. Comp. Med 2007, 57:538-545.
47. Xu R., Hranilovic D., Fetsko L.A., Bucan M., Wang Y. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol. Psychiatry 2002, 7:1075-1082.
48. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53:337-351.
49. Yu L., Schwarzschild M.A., Chen J.F. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neurosci. Lett 2006, 393:31-35.